The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Rationale and study design. the Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH)

American Heart Journal

Volumn 161, Issue 3, 2011, Pages

  McBride, Ruth ^a  

^a Axio Research LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; ATHEROSCLEROSIS; BEDTIME DOSAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBRAL REVASCULARIZATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 79952452422     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.11.017     Document Type: Article

References (27)

1. American Heart Association. Heart Disease and Stroke Statistics-2009 Update. American Heart Association. 2009. Dallas, TX, American Heart Association. May 8, 2009 Ref Type: Electronic Citation.
2. Cholesterol Treatment Trialists Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
3. Castelli W.P. Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study Can J Cardiol 4 Suppl A 1988 5A 10A
4. Assmann G., Schulte H., and von E.A. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport Atherosclerosis 124 Suppl 1996 S11 S20
5. Rubins H.B., Robins S.J., and Collins D. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418 (Pubitemid 29362514)
6. Gordon D.J., Probstfield J.L., and Garrison R.J. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15 (Pubitemid 19043669)
7. Brown B.G., Zhao X.Q., and Chait A. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592 (Pubitemid 33126837)
8. Brown B.G., Zhao X.Q., and Cheung M.C. Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence J Clin Lipidol 1 2007 88 94 (Pubitemid 46710835)
9. Cannon C.P., Braunwald E., and McCabe C.H. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2006 1495 1504
10. Barter P., Gotto A.M., and LaRosa J.C. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310 (Pubitemid 47481452)
11. Zhao X.Q., Krasuski R.A., and Baer J. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS) Am J Cardiol 104 2009 1457 1464
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
13. Brown B.G., Canner P.L., and McGovern M.E. Nicotinic acid. Chapter 25 C.M. Ballantyne, Clinical Lipidology: a companion to Braunwald's Heart Disease 2009 Elsevier Saunders
14. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
15. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
16. Canner P.L., Berge K.G., and Wenger N.K. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255 (Pubitemid 17208898)
17. Cahin-Hemphill L., Mack W.J., and Pogoda J.M. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up JAMA 264 1990 3013 3017
18. Zhao X.Q., Brown B.G., and Hillger L. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B Circulation 88 1993 2744 2753 (Pubitemid 23360201)
19. Taylor A.J., Sullenberger L.E., and Lee H.J. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517 (Pubitemid 39612564)
20. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 Curr Med Res Opin 22 2006 2243 2250 (Pubitemid 44789989)
21. Villines T.C., Stanek E.J., and Devine P.J. The ARBITER 6-HALTS trial (Arterial Biology for the investigation of the treatment Effects of Reducing Cholesterol 6:HDL and LDL Treatment Strategies in Atherosclerosis) final results and the impact of medication adherence, dose and treatment duration. J Am Coll Cardiol 55 2010 2721 2726
22. Chapman M.J., Redfern J.S., and McGovern M.E. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk Pharmacol Ther 126 2010 314 345
23. Kamanna V.S., and Kashyap M.L. Mechanism of action of niacin Am J Cardiol 101 2008 20B 26B
24. Frick M.H., Elo O., and Haapa K. Helsinki heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia; safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245 (Pubitemid 17147964)
25. Goldenberg I., Benderly M., and Sidi R. Relation of clinical benefit in raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial) Am J Cardiol 103 2009 41 45
26. Keech A., Simes R.J., Barter P. for the FIELD Study Investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial Lancet 366 2005 1849 1861
27. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 363 2010 1563 1574